Drug updated on 9/5/2024
Dosage Form | Powder (oral Inhalation; 62.5 mcg umeclidinium and 25 mcg vilanterol) |
Drug Class | Anticholinergics and long-acting beta2-adrenergic agonists |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Latest News
Summary
- Anoro Ellipta (umeclidinium bromide and vilanterol trifenatate) is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
- This summary is based on the review of 12 systematic review(s)/meta-analysis(es). [1-12]
- UMEC/VI demonstrated significant improvements in FEV1, ranking second highest in overall efficacy (SUCRA 93.5%) and showing the highest efficacy in trough FEV1 improvement (Emax 0.185 L).
- UMEC/VI provided greater FEV1 improvement compared to monotherapies and placebo, with a 58% reduction in exacerbation risk.
- UMEC/VI consistently improved SGRQ scores and TDI focal scores across various studies, with improvements comparable to or greater than other LAMA/LABA combinations.
- UMEC/VI also reduced the need for rescue medication and demonstrated significant reductions in COPD exacerbations.
- UMEC/VI significantly reduced the annualized rate of moderate/severe exacerbations and showed a 58% reduction in exacerbation risk compared to placebo.
- The drug also exhibited a lower overall risk of exacerbations in a network meta-analysis compared to other LAMA/LABA combinations.
- No significant differences were observed in all-cause mortality and serious adverse cardiovascular events among LABA/LAMA FDCs.
- UMEC/VI demonstrated a similar safety profile to other LABA/LAMA combinations, showing no significant differences in major adverse cardiovascular events or pneumonia.
- UMEC/VI was well-tolerated and safe in general COPD populations and across different medication subgroups, including maintenance-naïve and ICS-free patients.
- There is no population type or subgroup information available in the reviewed studies.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Anoro Ellipta (umeclidinium bromide and vilanterol trifenatate) Prescribing Information. | 2023 | GlaxoSmithKline, Research Triangle Park, NC |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
2023 Canadian Thoracic Society Guideline on Pharmacotherapy in Patients with Stable COPD. | 2023 | Canadian Journal of Respiratory, Critical Care, and Sleep Medicine |
2022 GINA Report, global strategy for asthma management and prevention. | 2022 | Global Initiative for Asthma |
LABA/LAMA as First-Line Therapy for COPD: A Summary of the Evidence and Guideline Recommendations. | 2022 | Journal of Clinical Medicine |
Spanish COPD guidelines (GesEPOC) 2021: Updated pharmacological treatment of stable COPD. | 2021 | Archivos de Bronconeumologia |
2020 Gold pocket guide to COPD diagnosis, management, and prevention. | 2020 | Global Initiative for Chronic Obstructive Lung Disease |
COPD-X Concise Guide. | 2020 | Lung Foundation Australia |
Canadian Thoracic Society Clinical Practice Guideline on pharmacotherapy in patients with COPD – 2019 update of evidence. | 2019 | Canadian Journal of Respiratory, Critical Care, and Sleep Medicine |